MICROBIX

MICROBIX PRESENTATION

Advancing Global Health By Supporting Next-Generation Diagnostics

Autumn 2026

TSX: MBX | OTCQX: MBXBF







Forward-Looking Statements

This presentation contains forward-looking statements about trends and objectives.

Risks and uncertainties relating to such statements could cause actual outcomes to differ materially.

Such risks include, among others, those related to operations, customers or markets, growth drivers, products or technologies, product pricing or costs, development projects, financial results, regulatory matters, access to markets, and access to capital.

Forward-looking statements represent Microbix's current judgement, and it disclaims any obligation to update them except as required by applicable laws.



Microbix – Supporting Next-Generation Diagnostics

Established Global Diagnostics Supplier

- 30+ year track record supplying antigens to 100+ diagnostic manufacturers
- Deep integration in immunoassay workflows → high switching costs
- Leader in native antigens, have added full recombinant capabilities.

Addition of Higher-Value, Faster-Growing QAPs™

- Expanding quality assessment & control products (QAPs™) offering
- Serving:
  - Proficiency testing organizations
  - Diagnostic test-makers
  - Clinical laboratories
- Positioned for recurring, higher-margin revenue growth

Stabilized Base, Positioned for Growth

- F2026 expected revenue of $16-17M following client-specific headwinds
- Return to growth supported by:
  - New QAPs customer wins
  - Expanded product portfolio
  - Cross-selling into existing customer base

Microbix – Supporting Next-Generation Diagnostics (Continued)

Strong Financial Position Enables Execution

- ~$11M in total liquidity (cash + unused credit); low leverage (D/E[1] ~0.40)
- History of EBITDA[1] and net income generation
- Significant operating leverage at higher revenue levels

Built for Scale

- 3 facilities + automation + regulatory infrastructure
- Capacity to support $100M+ revenue without major capex
- Current Net Earnings Breakeven at ~$22 million in annual revenues.

Aligned Capital Allocation

- >12.5 M shares repurchased across annual “NCIB” plans since Oct. 2022
- ~16% insider ownership
- Potential to benefit from Dx sector innovation and “life science tools” sector growth & consolidation

1 - Denotes non-GAAP financial measure, as defined in subsection 6.1(e) of National Instrument 52-112 - Non-GAAP and Other Financial Measures Disclosure (“NI 52-112”). Please refer to the “Non-GAAP Measures” section in the appendix to this presentation for further information.

Financials – Microbix Capital Structure

TSX: MBX • OTCQX: MBXBF

Current Price	**$0.295 (2026-11-13)**
Shares Outstanding (Basic)	**137.2M****
(Fully Diluted)	**168.5M****
52 Week High	**$0.325**
52 Week Low	**$0.21**
Market Cap	**$40.5M**
Avg. Daily Volume	**~50K (3 month)**
Cash and Line of Credit	**~$11.1M****
Longer Term Debt	**$2.8M BDC & Govt.** $4.0M debentures***

1-Year Share Price

Nov 17, 2025 – Nov 13, 2026



Analyst Coverage

bloom burton & co

David Martin

Target Price: $0.40

KRC INSIGHTS

Bruce Krugel

Target Price: $0.55

Active Share Buyback Program ("NCIB") For up to 5% of issued & outstanding per year.

**Convertible at $0.23 ** As of June 30, 2026*

Experienced Leadership Team with Deep Diagnostics & Commercial Expertise

Cameron L. Groome

CEO, President, and Director

- Has served on the MBX BoD and AC since 2012 and was appointed CEO in 2017.
- 30+ years' experience in senior life sciences and capital markets roles.
- Successful leader, executive, director, and advisor for public and private companies.

Jim Currie, CPA

Chief Financial Officer

- Joined MBX as CFO in 2016 after several CFO roles and a VP of Finance role at MDS SCIEX, a global leader in life science and analytical technologies.
- Jim holds a Bachelor of Commerce, and both CPA and CMA designations.

Ken Hughes, Ph.D.

Chief Operating Officer

- Executive and biomedical scientist with 25 years of experience in biotech and pharma.
- Previously was CEO of iTP Biomedica, VP of Sci. & Reg. Affairs at Innovative Medicines Canada, and Co-founder and Advisory Board member of PlantForm Corporation.

Phil Casselli

Sr. V.P. Business Dev., Sales, & Marketing

- Manages MBX's relationship with over 100 makers of infectious disease diagnostics across multiple regions.
- He holds a Bachelor of Applied Science in Chemical Engineering and has more than 30 years' experience in the biotech and pharmaceutical industries.

Mark Luscher, Ph.D.

Senior Vice President, Scientific Affairs

- Responsible for scientific programs, he is a specialist in cell biology, immunovirology, and cytometry.
- He is an inventor on numerous patents and patent applications and oversees scientific and technological programs and initiatives related to MBX's products.

20+ Other Skilled Directors & Managers, and a total of 120+ Staff

Including but not limited to:

Steven Hagerman – Senior Director of Operations, Amer Alagic – Director of R&D, Daniel Costa – Director of Manufacturing, Bo Hollas – Director, QA & Compliance, Lucy Lin – Director of QC, and Pavel Zhelev – Director, Product Management.

Microbix Board of Directors

Experienced Board with Deep Healthcare, Pharma, and Governance Expertise

Martin Marino
Board Chairman

Mr. Marino has 30+ years of experience in corporate legal roles and executive management functions, with emphasis on transaction-based corporate development. He also has considerable experience in conflict resolution and litigation management.

Dr. Peter M. Blecher
Director

Dr. Blecher, a longtime ER physician and pain specialist for ~25 years, has founded or led multiple successful health-related businesses. He is now Managing Partner of the Durham Spine & Pain Institute and is a credentialed pain practitioner with both the American and Canadian Academies of Pain Medicine.

Mark A. Cochran, Ph.D.
HRGC Chair

Dr. Cochran was Executive Director of Johns Hopkins Medicine. His experience spans all levels of the drug discovery and development value chain, including operational and executive roles in the healthcare, venture capital, pharmaceutical, and biotech industries.

Vaughn C. Embro-Pantalony
AC Chair

Mr. Embro-Pantalony has held senior roles in life sciences at Bayer, Novopharm, and Terra, with a focus on licensing, business development, strategy. He is a Chartered Director and Audit Committee Certified through McMaster University.

Joe Renner — Director

Mr. Renner, Chairman of Zydus Pharmaceuticals, of Pennington, New Jersey, has more than 30 years' experience in the pharmaceutical industry. He has enjoyed a successful career leading businesses with many drug approvals in the United States.

Jennifer Stewart — Director

Ms. Stewart is the founder, President, & CEO of Syntax Strategic, a leading Canadian advocacy & communications firm. She is a recognized expert in the field & actively engaged in media, business, & community initiatives.

Cameron Groome — Director

Mr. Groome is CEO and President of Microbix.

Two Complementary Product Lines Supporting Global Diagnostics

Established base business with growing exposure to higher-value quality controls



We grow, purify, and inactivate many bacteria and viruses to make "Antigens," as critical ingredients in "Immunoassay" tests that detect antibodies in blood in order to assess exposure to, or immunity against, pathogens.

Antigen Sales - established base business (C$ 1,000s)





We create, make, and sell safe and stable mimetics of clinical patient-samples – as test-controls. Called quality assessment products (QAPs™), these medical devices are used to help make certain tests and test processes work reliably – to avoid "false negative" or "false positive" results.

QAPs Sales – growing as a % of revenue/time (C$ 1,000s)



Revenue Mix Reflects Transition: Antigens: long-term base business + QAPs: increasing contribution to growth

TEST INGREDIENTS – ANTIGENS

Established Core Business with Deep Customer Integration

Grows, purifies, and inactivates native bacteria and viruses for use as antigens for more than 100 leading international diagnostic companies. Microbix provides antigens on a large scale for major international diagnostic manufacturers, most often as a critical sole-source supplier.

ToRCH Antigens – Worldwide commercial leader

Respiratory Antigens – Broad range of pathogens

Childhood Disease Antigens – Unique offerings

Sexually Transmitted Infections – Full range

Tropical Disease Antigens – Insect-borne pathogens

Often a sole-source supplier to leading diagnostic companies



TEST CONTROLS – QUALITY ASSESSMENT PRODUCTS (QAPS™)

A higher-value, recurring segment of the diagnostics market

What QAPs Actually Do: Simulate real patient samples (e.g., as liquids, swabs, or tissue) to validate Dx assay performance. This is used across many QMS purposes, including for certifying lab competency and for ongoing test quality assurance.

Critical for Test Approval & Adoption

- Necessary to confirm accuracy of diagnostics.
- Importance across:
  - Antigen-based Tests
  - Molecular diagnostics (MDx/PCR)
  - Point-of-care testing (PoCTs)
  - Multiplex assays

Expanding Addressable Market

- Beyond Immunoassay antigen supply into:
  - PT/EQA providers
  - Dx test-makers
  - Clinical labs
  - Global screening programs (e.g., for cervical cancer)

Recurring & Scalable Revenue Model

- Ongoing demand for:
  - Lab certification
  - Lab QMS
  - Site/Staff Training
  - Test development
  - Dx lot QC release



Microbix is a Trusted Partner Across The Global Diagnostics Ecosystem

Microbix has been supporting international test makers for decades – its Antigens forming the heart of millions of Immunoassays. It has over 100 such customers, many ordering large amounts of product.

Over recent years, Microbix has added new categories of customers via its QAPs, expanding its addressable markets to include:

- Agencies that test the proficiency of clinical laboratories
- International makers of molecular and antigen tests
- Clinical laboratories in Canada, the U.S., and internationally

Disclosed relationships include the following companies:

Roche
American Proficiency Institute
Abbott
SEKISUI
BIOMÉRIEUX
Waters™ Advanced Diagnostics
QuidelOrtho™
Cepheid
CAP
Flinders University
Copan innovating together
SIEMENS Healthineers
r-biopharm®
SpeeDx
Seegene
LABQUALITY
emqn
Australian Centre for the Prevention of Cervical Cancer

Where Microbix Products are Used

World Map of Antigen and QAPs Distribution

Our Ingredients (Antigens) and Medical Devices (QAPs) are in use around the world.

Microbix products are available in more than 30 countries, directly or via partners.



Countries where Microbix products are available

ENSURING CONFIDENCE IN DIAGNOSTIC TESTS

Makers, Regulators, Users, & Payors Need Proof They Work

Our Products Help Ensure that Tests Actually Work. This is Critical for Correct Diagnosis and Treatment

Microbix makes essential products that enable diagnostic tests to be made and sold. Many next-generation Dx assays need Microbix products for approval & reimbursement.



AT THE CORE OF QUALITY

Kinlytic® – FDA-Approved, Fully Funded Drug with a Defined Path to Market

Microbix owns the BLA of a well-established thrombolytic drug. Partnered with Sequel Pharma, LLC for re-launch of cell-culture derived LMW urokinase

Kinlytic® Urokinase

Microbix's deep expertise in cell-culturing led to its securing rights to a clot-buster biological drug approved in the U.S. & Canada (used for clearing venous catheters & pulmonary emboli).

- To resume sales, production at a new site must be validated as equivalent to past batches.
- A path to market has been settled with U.S. FDA, with CDMOs to make drug substance & drug product.
- The U.S. monopoly market (for tPA) is ~US$ 400M just for the catheter clearance sub-indication.*



**Please see the Microbix MD&A and AIF for market-data reference information.*

Kinlytic® – An FDA-Approved Clot-Buster Drug

Refined project scope to first address the Catheter Clearance Indication & its U.S. market as initial value-driver

Sequel Pharma, LLC has secured 100% funding of ~US$ 35M to fully underwrite total project cost & risk

Multiple contacts with US FDA, and their provided guidance, support the regulatory approach to returning Kinlytic to the market

Major international CDMOs are now updating production processes, demonstrating comparability with the historical product, and commencing finished product manufacturing

In collaboration with Microbix, Sequel Pharma has the funding and technical expertise to return Kinlytic to market, providing a large additional opportunity – For **milestone payments up to US$ 31 million**, and **ongoing royalties** at a double-digit percentage of net sales.

Scaled Manufacturing & Regulatory Infrastructure to Support Growth

Significant capacity in place to support revenue expansion without major incremental capital

We Have Built Both Capabilities and Capacity To Secure New Product & Customer Opportunities

Built for Scale:

- 3 fully operational facilities across adjacent sites
- 120+ employees across production, QA/QC, and R&D
- Capacity to support significantly higher revenue levels

Regulatory & Product Depth:

- ~100 IVD molecular controls (REDx™) with CE Mark / FDA registration
- ~300 SKUs across antigens and QAPs
- Established regulatory and quality systems

Integrated Capabilities

- End-to-end: development, manufacturing, QC, QA
- Industrial-scale culturing of biological materials
- In-house scientific and synthetic biology expertise



Scaled Manufacturing Capacity Ready for Growth

We Have Built Both Capabilities and Capacity To Secure New Product & Customer Opportunities

QAP Production Capacity

- Liquid vial format: ~150,000 units/month capacity
- Dried swab format: ~200,000 units/month capacity

Automation & Efficiency

- Semi-automated and fully automated production lines
- Designed for consistent, scalable output

Product Development & Expansion

- Dedicated R&D and QC lab capacity
- Supports:
  - New product launches
  - Customer-specific solutions
  - Expansion into new testing categories



Operations - Expanding Product Line & Revenue

Microbix's product line is rapidly expanding, as is our base of customers. Just in the past months…

February 2026	– Welcomed The College of American Pathologists (CAP) as a QAPs client – to support multiple EQA/PT programs.
March 2026	– For Kinlytic urokinase clot-buster drug redevelopment, modernized "Drug Substance" manufacturing methods.
March 2026	– At EUROGIN, presented new HPV reference-materials to support cervical cancer screening based on self-collected samples.
April 2026	– At ESCMID Global, presented new QAPs to support QMS of testing for RNA viruses, based on synthesized phage constructs.
September 2026	– Formal qualification as a critical products supplier to five of the top-ten global in-vitro diagnostic test manufacturers.
October 2026	– At IPVS, presented a synthetic vaginal matrix to help validate HPV tests on self-collected samples.
November 2026	– At EMMD, presented synthetic DNA and phage-RNA QAP controls for QC of HCV molecular testing workflows.



2017 – 2026

Microbix – The Past 10 Years at a Glance

2017

New CEO & Recapitalization
Reinvestment into sales-driven businesses

Bioreactor Antigen Scale-Up
Began scale-up of bioreactor production

ISO 13485 certification initiated
Began process of certification to ISO 13485

Revenues Exceeded $10M
Sufficient sales to enable growth plans

2018

Facility Upgrades
Material upgrades to 265 Watline

Expanded QAPs offerings
Added 48 new QAPs to PT/EQA portfolio

ISO 13485 Certification Achieved
Achieved alongside existing ISO 9001

QAPs Sales of $1M
PT/EQA QAPs sales become material

2019

2nd Site Leased for QAPs
To expand mfg. of QAPs (235 Watline)

1st QAPs EU Registration (HPV)
First QAPs IVDD CE Mark for HPV

1st QAPs U.S. Registration (HPV)
First QAPs IVD FDA Registration for HPV

1st QAPs HPV Results Presented
HPV work presented at EMMD & EUROGIN

2020

COVID QAP Launched (March 2020)
COVID MDx QAP & PT/EQA made available

COVID QAPs Regulatory Approvals
COVID QAP FDA Reg & CE mark obtained

COVID Ag QAPs Launched
COVID Ag QAPs commercialized

COPAN FLOQSwabs Alliance
IP & Cobranding Alliance with COPAN

2021

Viral Transport Medium Creation
VTM made commercially available

VTM Supplied for Canada
VTM supply contract for Province of Ontario

3rd Site Leased for Reagents
To expand mfg. for VTM/QAPs (275 Watline)

COVID Variants-of-Concern QAPs
QAPs for COVID VOCs commercialized

2022

Onboarding of Synthetic Biology
Omicron COVID QAP & many more since

Software System Upgrading
Initiation of ERP & eQMS upgrades

HPV Workflow Validations
For Onclarity & Mswab via HPV QAPs

Conference Recognition of QAPs
Presentations at ESCMID, AACC & EMMD

2023

Canadian HPV Screening Support
1st Province for MDx HPV program

Australian STI Program Support
QAPs for TTANGO STI PoCT program

ERP & eQMS Go-Live
ERP and eQMS systems go-live, IVDR started

Multi-nation HPV MDx Support
Netherlands & Ireland begin use of QAPs

2024

1st Molecular Pathology QAP
HPV "FFPE" results presented at EUROGIN

Site 3 Commissioning Completed
Automated filling line PQ (275 Watline)

EU IVDR & CE Certification
First QAPs certified to IVDR standards

1st Pharmacogenomics QAP
QAP for urgent-need genetics PoCT

2025

Onboarding for Recombinants
Full recombinant antigen mfg. capabilities

Indo-Pacific HPV Screening Support
Eleven more nations begin use of HPV QAPs

Pathogen Access Expansion
Exclusive Supply Agreement with NCIPD

QUANTDx Launch at ADLM
Line of quantified reference materials

2026

Welcome of "CAP" as a Customer
World's largest PT/EQA scheme provider

Enhanced HPV Reference Materials
Launch of Cellularity-Normalized Samples

1st synthetic RNA QAP
Phage-encapsulated HCV RNA control

Formal Supplier Qualifications
With five of the top-ten Dx test-makers

Financials – The Past Several Years

Revenues, Current Ratio[1], Net Earnings, and EBITDA[1] **Have Repurchased (& cancelled) over 12.5 Million Shares**

C$ millions; fiscal years end Sept 30; full-year totals under each year

Q1 Q2 Q3 Q4

REVENUE



FY21	FY22	FY23	FY24	FY25	9M FY26
$18.6	$19.1	$16.5	$25.4	$18.6	$11.7

CURRENT RATIO[1]



NET EARNINGS



FY21	FY22	FY23	FY24	FY25	9M FY26
$3.2	$1.8	($0.0)	$3.5	($2.2)	($3.4)

EBITDA[1]



FY21	FY22	FY23	FY24	FY25	9M FY26
$5.7	$3.6	$1.5	$5.5	$0.1	($1.4)

1 - Denotes non-GAAP financial measure, as defined in subsection 6.1(e) of National Instrument 52-112 - Non-GAAP and Other Financial Measures Disclosure ("NI 52-112"). Please refer to the "Non-GAAP Measures" section in the appendix to this presentation for further information.

Clear Path to Revenue Growth and Product Mix Expansion

Leveraging existing relationships, expanding product adoption, and entering new markets

1. Expand Within Existing Customers

- Cross-sell QAPs into >100 existing diagnostic customers
- Increase revenue per customer through broader product mix

2. Add New High-Value Customers

- Target diagnostic Cos. with >$1M annual potential revenues
- Expand relationships with EQA providers and laboratories

3. Grow QAPs Portfolio

- Launch new controls across:
  - Molecular & PoC testing
  - Multiplex / syndromic panels
  - Emerging infectious disease categories

4. Benefit from Structural Industry Tailwinds

- Increasing demand for:
  - Quality controls
  - Regulatory compliance
  - More complex diagnostic testing

Key Takeaways about Microbix

1. Established Diagnostics Platform with Global Customers

- Trusted supplier to 100+ diagnostic companies, EQA providers, and labs
- Embedded in the global diagnostics ecosystem

2. Clear Path to Growth Through QAPs Expansion

- Increasing adoption of higher-value quality controls
- Cross-selling into existing customer base

3. Operating Leverage from Existing Infrastructure

- Capacity already in place to support growth
- Incremental revenue expected to drive margin expansion

4. Additional Upside from Partnered Assets (Kinlytic®)

- FDA-approved biologic with defined path to market
- Milestones and royalty potential with project costs fully-funded

Microbix has become a "go-to" partner regarding next-generation diagnostic tests. Its QAPs are often essential for approval/adoption of new lab-based and Point-of-Care tests.

Capabilities	Goals
Biology & Mfg.	+Δ Revenues
QC/QA/Regulatory	+Δ Earnings
Biz Dev & Mgmt	+Δ Share Value



Positioned for Improving Revenue Mix, Margin Expansion, and Long-Term Value Creation



Thank You

Cameron Groome
CEO, President, and Director
cameron.groome@microbix.com

MICROBIX

TSX: MBX | OTCQX: MBXBF

Appendix regarding non-GAAP Financial Measures

This appendix provides important context concerning the non-GAAP financial measure “EBITDA” referenced on slides 3 and 19 earlier herein.

Non-GAAP (non-IFRS) Measures Discussion

In addition to disclosing detailed operating results in accordance with generally-accepted accounting principles (GAAP), Microbix provides supplementary non-GAAP financial measures to consider in evaluating the company’s operating performance such as EBITDA.

EBITDA represents net earnings of the company before the deduction of the expenses of interest, taxes, depreciation and amortization, with all such terms other than EBITDA as defined by International Financial Reporting Standards (IFRS). EBITDA however is not a formally-defined term under IFRS or by GAAP.

Management believes the EBITDA (non-GAAP) financial measure may assist investors in assessing an investment in the Company’s shares given that it may provide additional insight into the Company’s financial performance, particularly for those investors who may regularly review the results of companies partially based on this informal yet widely-used financial measure.

All readers, regardless of their level of sophistication, are cautioned that EBITDA is not a formally-defined performance measure, does not have any standardized meaning under IFRS, and may differ from similar computations as reported by other similar entities. Accordingly, the EBITDA reported herein by Microbix may not be comparable to this measure as reported by other entities. EBITDA should therefore not be considered either in isolation or as a substitute for formally-defined financial measures or reports prepared in accordance with IFRS.

Appendix regarding non-GAAP Financial Measures (Continued)

Quantitatively, EBITDA as defined above may be reconciled to IFRS-defined and reported Net Earnings by the deduction from EBITDA of the IFRS-defined and reported expense measures of interest, taxes, depreciation, and amortization. Net Earnings of Microbix for fiscal 2021 through 2025 and the nine-months ended June 30, 2026 were C$ 3.2, 1.8, 0.0, 3.5, (2.2), & (3.4) million respectively, as compared to EBITDA of C$ 5.7, 3.6, 1.5, 5.5, 0.1, & (1.4) million for the same respective periods.

Debt-to-Equity, also known as D/E, is a financial ratio comprised of the firm's total debt over its shareholders' equity, sometimes used to assess financial leverage.

Current Ratio is a financial ratio comprised of the firm's total current assets over its total current liabilities, sometimes used to assess financial liquidity.

Appendix regarding non-GAAP Financial Measures (Continued)

Reconciliation of Non-GAAP (non-IFRS) Measure

Quarterly EBITDA Fiscal 2021 to 2026

2021	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	$130,819	$807,463	$1,516,178	$778,930	$3,233,390
Interest	262,403	265,996	273,182	801,624	1,603,205
Taxes	-	-	-	-	
Depr'n & Amort'n	174,109	216,026	204,985	226,920	822,040
EBITDA	**$567,331**	**$1,289,485**	**$1,994,345**	**$1,807,474**	**$5,658,635**

2022	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	$880,778	$733,489	$638,502	($464,080)	$1,788,689
Interest	240,750	203,125	170,454	129,961	744,290
Taxes	-	-	-	77,234	77,234
Depr'n & Amort'n	223,084	258,292	263,922	291,102	1,036,400
EBITDA	**$1,344,612**	**$1,194,906**	**$1,072,878**	**$34,217**	**$3,646,613**

2023	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	($1,299,262)	$31,616	($769,108)	$1,997,271	($39,483)
Interest	97,078	91,319	102,490	90,749	381,636
Taxes	-	-	-	-	
Depr'n & Amort'n	241,294	302,430	304,219	309,226	1,157,169
EBITDA	**($960,890)**	**$425,365**	**($362,399)**	**$2,397,246**	**$1,499,322**

2024	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	$2,455,379	$377,730	$246,746	$440,324	$3,520,179
Interest	114,485	81,326	(81,432)	119,890	234,269
Taxes	-	-	-	150,563	150,563
Depr'n & Amort'n	382,431	404,154	426,655	399,573	1,612,813
EBITDA	**$2,952,295**	**$863,210**	**$591,969**	**$1,110,350**	**$5,517,824**

2025	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	$856,962	$20,664	($1,642,776)	($1,480,662)	($2,245,812)
Interest	113,129	157,962	156,489	168,314	595,894
Taxes	-	-	-	(55,726)	(55,726)
Depr'n & Amort'n	434,942	428,043	444,846	471,525	1,779,356
EBITDA	**$1,405,033**	**$606,669**	**($1,041,441)**	**($896,549)**	**$73,712**

2026	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	($1,167,177)	($1,430,338)	($806,762)		
Interest	180,196	194,011	211,449		
Taxes	-	-	-		
Depr'n & Amort'n	456,294	463,488	471,728		
EBITDA	**($530,687)**	**($772,839)**	**($123,585)**		

Cutting-Edge Capabilities & Real Revenue Growth Opportunities

Both Dx & Rx Projects Self-Funding with Great Prospects

Expanding Earnings Potential to Drive Share Price Appreciation

Appendix regarding non-GAAP Financial Measures (Continued)

Reconciliation of Non-GAAP (non-IFRS) Measure

Quarterly EBITDA Fiscal 2021 to 2026

2023	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	($1,299,262)	$31,616	($769,108)	$1,997,271	($39,483)
Interest	97,078	91,319	102,490	90,749	381,636
Taxes	-	-	-	-	
Depr'n & Amort'n	241,294	302,430	304,219	309,226	1,157,169
EBITDA	**($960,890)**	**$425,365**	**($362,399)**	**$2,397,246**	**$1,499,322**

2024	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	$2,455,379	$377,730	$246,746	$440,324	$3,520,179
Interest	114,485	81,326	(81,432)	119,890	234,269
Taxes	-	-	-	150,563	150,563
Depr'n & Amort'n	382,431	404,154	426,655	399,573	1,612,813
EBITDA	**$2,952,295**	**$863,210**	**$591,969**	**$1,110,350**	**$5,517,824**

Cutting-Edge Capabilities & Real Revenue Growth Opportunities

Both Dx & Rx Projects Self-Funding with Great Prospects

Expanding Earnings Potential to Drive Share Price Appreciation

Appendix regarding non-GAAP Financial Measures (Continued)

Reconciliation of Non-GAAP (non-IFRS) Measure

Quarterly EBITDA Fiscal 2021 to 2026

2025	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	$856,962	$20,664	($1,642,776)	($1,480,662)	($2,245,812)
Interest	113,129	157,962	156,489	168,314	595,894
Taxes	-	-	-	(55,726)	(55,726)
Depr'n & Amort'n	434,942	428,043	444,846	471,525	1,779,356
EBITDA	**$1,405,033**	**$606,669**	**($1,041,441)**	**($896,549)**	**$73,712**

2026	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	($1,167,177)	($1,430,338)	($806,762)		
Interest	180,196	194,011	211,449		
Taxes	-	-	-		
Depr'n & Amort'n	456,294	463,488	471,728		
EBITDA	**($530,687)**	**($772,839)**	**($123,585)**		

Cutting-Edge Capabilities & Real Revenue Growth Opportunities

Both Dx & Rx Projects Self-Funding with Great Prospects

Expanding Earnings Potential to Drive Share Price Appreciation